This review explains how hormonal states across the female lifespan—such as menstrual cycle phases, pregnancy and postpartum periods, perimenopause, menopause, and hormone therapy—may influence how the body and brain respond to psilocybin. Hormones like estrogen can shape serotonin signaling and neuroplasticity, suggesting that timing, dose, and integration may need personalization. This is theoretical, based on existing neurobiology and early clinical observations—not direct human trials linking cycle phase to psilocybin outcomes yet.